Colinz Labs

When is the next results date for Colinz Labs?

No Upcoming Board Meetings

Who are in the management team of Colinz Labs?

As of March 2023, the management team of Colinz Labs consists of L S Mani (Director & Company Secretary), N K Menon (Whole-time Director), Vasant K Bhat (Independent Director), and A Krishna Kumar (Independent Director). They are responsible for the company's governance and operations.

As of March 2023, the management team of Colinz Labs includes the following individuals:<BR><BR>1. L S Mani - Director & Company Secretary<BR>2. N K Menon - Whole-time Director<BR>3. Vasant K Bhat - Independent Director<BR>4. A Krishna Kumar - Independent Director<BR><BR>These members play key roles in the governance and operational management of the company.

What does Colinz Labs do?

Colinz Laboratories Ltd is a pharmaceutical and biotechnology company that manufactures various pharmaceutical formulations. As of March 2025, it reported net sales of 1 Cr and a market capitalization of Rs 29 Cr.

Overview: <BR>Colinz Laboratories Ltd is a pharmaceutical and biotechnology company that manufactures a wide variety of pharmaceutical formulations.<BR><BR>History: <BR>Colinz Laboratories Ltd was incorporated as a Private Limited Company in 1986 and converted into a Public Limited Company in 1995, the same year it began its manufacturing and marketing activities. The latest quarterly results reported net sales and net profit for March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 1 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 29 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 29.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.77 <BR>Return on Equity: 5.35% <BR>Price to Book: 3.06<BR><BR>Contact Details: <BR>Address: A-101 Pratik Industrial Estate, Mulund Goregaon Link Road Mumbai Maharashtra : 400078 <BR>Tel: 91-022-25668002/8003 <BR>Email: colinzlabs@yahoo.com <BR>Website: http://www.cindoc-cll.in

Has Colinz Labs declared dividend?

No Dividend History Available

Who are the peers of the Colinz Labs?

Colinz Labs' peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, and others. While Sun Pharma and Dr Reddy's Labs show excellent management and growth, Colinz Labs has below-average growth and management risk, with a 1-year return of 66.49%.

Peers: The peers of Colinz Labs are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Zenith Health, Ishita Drugs, Chemo Pharma Lab, Phaarmasia, and Desh Rakshak.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Below Average management risk is found at Colinz Labs, Zenith Health, Ishita Drugs, Phaarmasia, and Desh Rakshak. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is noted for Colinz Labs, Divi's Lab., Torrent Pharma, Zenith Health, Ishita Drugs, Phaarmasia, and Desh Rakshak. Excellent capital structure is seen at Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, while Good capital structure is present at Colinz Labs, Torrent Pharma, and Zenith Health, and the rest have Below Average or do not qualify.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Desh Rakshak at 422.50%, while the lowest is Phaarmasia at -24.74%. Colinz Labs has a 1-year return of 66.49%, which is significantly higher than Phaarmasia but lower than Desh Rakshak. Additionally, peers with negative six-month returns include Zenith Health, Phaarmasia, and Chemo Pharma Lab.

What is the technical trend for Colinz Labs?

As of 26 May 2025, Colinz Labs shows a bullish technical trend supported by positive daily and weekly indicators, although caution is advised due to mildly bearish signals from the monthly MACD and Dow Theory.

As of 26 May 2025, the technical trend for Colinz Labs has changed from mildly bullish to bullish. The weekly MACD is bullish, supporting the upward momentum, while the daily moving averages also indicate a bullish stance. The KST is bullish on both weekly and monthly time frames, reinforcing the positive outlook. However, the monthly MACD and Dow Theory show mildly bearish signals, suggesting some caution. Overall, the current technical stance is bullish with moderate strength, driven primarily by the bullish indicators on the daily and weekly charts.

Who are the top shareholders of the Colinz Labs?

The top shareholder of Colinz Labs is Mani L S, holding 34.45% of the shares, with no pledged promoter holdings. The highest public shareholder is Dipakbhai Haribhai Gaudani at 1.31%, while individual investors collectively own 31.04%.

The top shareholders of Colinz Labs include the promoters, with Mani L S holding the largest share at 34.45%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. The highest public shareholder is Dipakbhai Haribhai Gaudani, who holds 1.31%. Additionally, individual investors collectively hold 31.04% of the shares.

How big is Colinz Labs?

As of 24th July, Colinz Laboratories Ltd has a market capitalization of 23.00 Cr, with recent net sales of 6.53 Cr and a net profit of 0.50 Cr. Shareholder's funds are 8.95 Cr and total assets amount to 11.36 Cr.

As of 24th July, Colinz Laboratories Ltd has a market capitalization of 23.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Colinz Laboratories Ltd reported Net Sales of 6.53 Cr and a Net Profit of 0.50 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 8.95 Cr and Total Assets of 11.36 Cr.

How has been the historical performance of Colinz Labs?

Colinz Labs has experienced a downward trend in net sales, reporting 6.53 Cr in March 2025, down from 7.03 Cr in March 2024. Despite a slight increase in profit after tax to 0.50 Cr, negative cash flow and declining revenues raise concerns about its financial stability.

Answer:<BR>The historical performance of Colinz Labs shows a fluctuating trend in net sales and profits over the years, with a slight decline in recent periods.<BR><BR>Breakdown:<BR>Colinz Labs reported net sales of 6.53 Cr in March 2025, down from 7.03 Cr in March 2024 and 7.15 Cr in March 2023, indicating a downward trend in revenue. The total operating income mirrored this decline, remaining at 6.53 Cr in March 2025. The company's total expenditure, excluding depreciation, decreased to 6.03 Cr in March 2025 from 6.49 Cr in March 2024. Operating profit (PBDIT) was 0.80 Cr in March 2025, slightly lower than 0.82 Cr in March 2024, while profit before tax was 0.62 Cr, down from 0.65 Cr the previous year. Profit after tax showed a modest increase to 0.50 Cr in March 2025 from 0.49 Cr in March 2024. The company's total assets rose to 11.82 Cr in March 2025 from 11.36 Cr in March 2024, and total liabilities also increased to 11.82 Cr from 11.36 Cr. Cash flow from operating activities turned negative at -1.00 Cr in March 2025, contrasting with a positive inflow of 1.00 Cr in March 2024. Overall, while Colinz Labs has shown some resilience in profit margins, the decline in sales and cash flow raises concerns about its financial stability.

Is Colinz Labs overvalued or undervalued?

As of November 3, 2025, Colinz Labs is overvalued with a PE ratio of 42.76 and a year-to-date decline of 35.64%, indicating a concerning long-term outlook despite a recent short-term gain.

As of 3 November 2025, Colinz Labs has moved from a fair to an expensive valuation grade. The company is currently overvalued, with a PE ratio of 42.76, an EV to EBIT of 15.61, and a ROE of 5.07%. In comparison to its peers, Sun Pharma has a PE of 35.62 and an EV to EBITDA of 24.18, while Cipla shows a more attractive PE of 22.44 and an EV to EBITDA of 5.66, highlighting Colinz Labs' relatively high valuation metrics.<BR><BR>Despite a recent uptick in stock price, with a 1-week return of 3.46% compared to a -0.94% return on the Sensex, the overall performance year-to-date shows a decline of 35.64% against a 7.47% increase in the Sensex. This suggests that while there may be short-term gains, the long-term outlook for Colinz Labs remains concerning given its current overvaluation in the context of its peers.

Are Colinz Laboratories Ltd latest results good or bad?

Colinz Laboratories Ltd's latest Q3 FY26 results are largely negative, with a 2.88% increase in revenue to ₹1.43 crores but a significant 42.86% drop in net profit to ₹0.08 crores, indicating challenges in profitability and operational efficiency. The declining PAT margin raises concerns about the company's long-term viability.

Colinz Laboratories Ltd's latest results for Q3 FY26 present a mixed picture, but overall, they lean towards the negative side. While the company reported a slight increase in revenue, with net sales rising by 2.88% quarter-on-quarter to ₹1.43 crores, its net profit fell significantly by 42.86% to ₹0.08 crores. This indicates a troubling decline in profitability despite stable revenue.<BR><BR>Moreover, the company's PAT margin has dropped sharply from 10.07% in the previous quarter to 5.59%, reflecting deteriorating operational efficiency. The operating margin did improve slightly to 6.99%, but this is still below the levels achieved in previous quarters. <BR><BR>The overall financial performance suggests that Colinz Laboratories is struggling with significant challenges, including weak capital efficiency and persistent margin volatility. The company's inability to achieve consistent growth and maintain profitability raises concerns about its long-term viability. Given these factors, the latest results can be considered bad, highlighting fundamental issues that need to be addressed for any potential recovery.

Should I buy, sell or hold Colinz Laboratories Ltd?

Why is Colinz Laboratories Ltd falling/rising?

As of 17-Mar, Colinz Laboratories Ltd's stock price is rising to Rs 42.94, reflecting a 4.76% increase. Despite this rise, the stock has declined 22.41% over the past month and shows signs of reduced investor participation.

As of 17-Mar, Colinz Laboratories Ltd's stock price is rising, currently at Rs 42.94, reflecting a change of Rs 1.95 or 4.76% increase. This upward movement is notable as the stock has outperformed its sector by 4.48% today. Additionally, the stock opened with a significant gain of 4.88%, indicating positive market sentiment. <BR><BR>Today marks a trend reversal for Colinz Laboratories, as the stock has gained after three consecutive days of decline. It reached an intraday high of Rs 42.99, showcasing strong buying interest. However, it is important to note that the stock's performance over the past month has been negative, with a decline of 22.41%, and it has also seen a decrease of 19.93% year-to-date. <BR><BR>Despite the current rise, there are signs of falling investor participation, as the delivery volume has decreased by 0.15% compared to the 5-day average. The stock's liquidity remains adequate for trading, but it is trading below several longer-term moving averages, which may indicate underlying weaknesses. Overall, while the stock is currently rising, its recent history and investor participation suggest a complex situation.

Why is Colinz Laboratories Ltd falling/rising?

As of 18-Mar, Colinz Laboratories Ltd's stock price is rising to Rs 44.89, up 4.52% due to recent trading performance and increased investor interest. Despite longer-term declines, the stock shows a positive short-term shift with significant gains over the last two days.

As of 18-Mar, Colinz Laboratories Ltd's stock price is rising, currently at Rs 44.89, reflecting an increase of Rs 1.94 or 4.52%. This rise can be attributed to several factors observed in the recent trading performance. Notably, the stock has outperformed its sector by 4.25% today and has experienced consecutive gains over the last two days, accumulating a total return of 9.51% during this period. <BR><BR>Despite opening the day with a loss of 4.89%, the stock managed to touch an intraday high of Rs 44.91, indicating a recovery from its earlier dip. The trading activity also shows a significant increase in investor participation, with delivery volume rising by 82.06% compared to the 5-day average, suggesting heightened interest among investors. <BR><BR>While the stock has shown a decline over longer periods, such as a 14.63% drop over the past month and a 32.20% decrease over the past year, the recent performance indicates a positive shift in sentiment, at least in the short term. The stock's current price is higher than its 5-day moving averages, although it remains below the longer-term moving averages. This combination of factors contributes to the stock's upward movement as of the latest trading session.

Why is Colinz Laboratories Ltd falling/rising?

As of 19-Mar, Colinz Laboratories Ltd's stock price is rising to Rs 46.80, up 4.23%. This increase is driven by strong short-term performance, increased investor interest, and a significant rise in delivery volume, despite long-term fundamental weaknesses.

As of 19-Mar, Colinz Laboratories Ltd's stock price is rising, currently at Rs 46.80, reflecting a change of 1.9 (4.23%) upward. This increase can be attributed to several factors. Firstly, the stock has outperformed its sector by 6.38% today and has been on a consecutive gain streak for the last three days, accumulating a total return of 14.17% during this period. Additionally, the stock opened with a gain of 4.65% today and reached an intraday high of Rs 46.99.<BR><BR>Investor participation has also increased, as indicated by a significant rise in delivery volume, which was up by 175.01% compared to the five-day average. This suggests a growing interest among investors, contributing to the upward momentum of the stock price. Furthermore, despite the stock's negative performance over the past year (-32.68%), it is currently trading at a discount compared to its peers, with an attractive valuation reflected in its Price to Book Value of 1.2.<BR><BR>However, it is important to note that while the stock is experiencing a rise in the short term, it has shown weak long-term fundamental strength, with a -1.13% CAGR growth in net sales over the last five years and a low return on equity of 4.90%. Despite these concerns, the current positive momentum is primarily driven by recent gains and increased investor activity.

Why is Colinz Laboratories Ltd falling/rising?

As of 20-Mar, Colinz Laboratories Ltd's stock price is 45.99, down 1.75% and underperforming its sector. The stock has declined 14.25% year-to-date and 36.99% over the past year, indicating short to medium-term struggles despite a strong five-year return of 480.68%.

As of 20-Mar, Colinz Laboratories Ltd's stock price is currently at 45.99, reflecting a decrease of 0.82, or 1.75%. The stock has underperformed its sector by 3.45% today and has experienced a trend reversal, falling after three consecutive days of gains. <BR><BR>In terms of performance over various periods, the stock has shown a significant decline of 14.25% year-to-date and a staggering 36.99% drop over the past year. Although it has performed well over the last five years with a return of 480.68%, the recent trends indicate a struggle in the short to medium term. <BR><BR>Additionally, while the stock's delivery volume increased by 56.77% against the five-day average, suggesting rising investor participation, it remains lower than the 50-day, 100-day, and 200-day moving averages, indicating a lack of sustained upward momentum. Overall, the combination of recent underperformance, a trend reversal, and a significant decline over the past year contributes to the current falling stock price of Colinz Laboratories Ltd.

Why is Colinz Laboratories Ltd falling/rising?

As of 23-Mar, Colinz Laboratories Ltd's stock price is Rs 43.70, down 4.98%, continuing a two-day decline of 6.64%. The stock has underperformed relative to its sector and shows a significant decrease in trading volume, indicating reduced investor participation and negative sentiment.

As of 23-Mar, Colinz Laboratories Ltd's stock price is falling, currently at Rs 43.70, which reflects a decrease of Rs 2.29 or 4.98%. This decline is part of a broader trend, as the stock has been losing value for the past two days, resulting in a total drop of 6.64% during this period. Today, the stock opened with a loss of 4.98% and has not traded above this opening price, indicating a lack of upward momentum.<BR><BR>In terms of performance relative to the sector, Colinz Laboratories has underperformed, with a performance today that is 1.41% lower than its sector average. Additionally, the stock's trading volume has decreased significantly, with a delivery volume of 1.86k on 20 March, which is down 32.35% compared to the 5-day average. This suggests a decline in investor participation, which can further contribute to the falling stock price.<BR><BR>The stock's performance over different time frames also shows a negative trend, with a year-to-date decline of 18.52% and a one-year drop of 42.97%. Although it has performed well over the last five years with a gain of 446.25%, the recent trends indicate a significant downturn that is affecting investor sentiment and contributing to the current price decline.

Why is Colinz Laboratories Ltd falling/rising?

As of 24-Mar, Colinz Laboratories Ltd's stock price is at 43.48, reflecting a decline of -0.5% and a significant drop of -45.96% over the past year, indicating a bearish trend and lack of investor confidence. The stock is underperforming its sector and has seen a drastic decrease in trading activity.

As of 24-Mar, Colinz Laboratories Ltd's stock price is falling, currently at 43.48, which reflects a change of -0.22 or -0.5%. The stock has been underperforming, having lost -7.11% over the last three days, and it has consistently declined for three consecutive days. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend.<BR><BR>Investor participation has also decreased significantly, with delivery volume dropping by -63.88% compared to the 5-day average. This decline in trading activity suggests a lack of confidence among investors. Furthermore, the stock has underperformed its sector by -1.62% today, contributing to the overall negative sentiment surrounding it. <BR><BR>In the broader context, the stock has experienced a substantial decline of -45.96% over the past year, compared to a mere -5.02% drop in the benchmark Sensex, highlighting its relative weakness in the market.

Why is Colinz Laboratories Ltd falling/rising?

As of 25-Mar, Colinz Laboratories Ltd's stock price is at 43.48, unchanged from the previous session. The stock has declined 18.93% year-to-date and 48.53% over the past year, underperforming the market and showing weak fundamentals, leading to a perception of it as a strong sell.

As of 25-Mar, Colinz Laboratories Ltd's stock price is currently at 43.48, showing no change from the previous trading session. The stock has been experiencing a significant decline, with a year-to-date drop of 18.93% and a staggering 48.53% decrease over the past year. This underperformance is starkly contrasted by the broader market, as the Sensex has only fallen by 11.67% during the same period.<BR><BR>The stock's performance today has underperformed its sector by 1.89%, and it is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. Additionally, there has been a notable decline in investor participation, with delivery volume on March 24 falling by 96.33% compared to the 5-day average. This suggests a lack of interest from investors, which can contribute to downward pressure on the stock price.<BR><BR>Financially, the company has weak long-term fundamentals, evidenced by a -1.13% compound annual growth rate (CAGR) in net sales over the last five years and a poor EBIT to interest ratio of 0.37, indicating challenges in servicing its debt. The return on equity (ROE) stands at a low 4.90%, reflecting low profitability relative to shareholders' funds. Despite having an attractive valuation with a price-to-book value of 1.1, the stock's performance has been significantly worse than its peers, leading to a perception of it being a strong sell.<BR><BR>In summary, the combination of poor financial performance, declining investor interest, and underperformance relative to the market and sector are key factors contributing to the falling stock price of Colinz Laboratories Ltd.

Which are the latest news on Colinz Labs?